Receptors, Islet Amyloid Polypeptide
Novo Nordisk Plans Phase 3 Trials for Next-Generation Obesity Drug Amycretin
Novo Nordisk; amycretin; obesity; clinical trials; Phase 3; GLP-1; amylin receptor; weight loss; subcutaneous; oral
Actionable Insights Powered by AI
Novo Nordisk; amycretin; obesity; clinical trials; Phase 3; GLP-1; amylin receptor; weight loss; subcutaneous; oral